Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
Office:
Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
DURECT Corporation announced top-line results from its phase IIa clinical trial of DUR-928 for mild to moderate plaque psoriasis. While the drug was well tolerated, it did not demonstrate a meaningful benefit over placebo in the trial, and DURECT will no longer be pursuing this indication, instead focusing on trials of DUR-928 for nonalcoloholic steatohepatitis (NASH). Will our extensive experience with clinical trials, Yourway knows the importance of agile decision making to determine which trials to terminate and which to pursue.
Global Clinical Supplies Group (GCSG)
October 14-16, 2025
Hungary, Budapest
Clinical Outsourcing Group (COG)
October 21-22, 2025
Burlingame, California
Case study: Coordinating a complex intercontinental shipment on a short timeline